THE AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY
🇨🇳China
Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fasted Condition
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 26
- Registration Number
- NCT04438733
- Locations
- 🇨🇳
Phase I Clinical Research Center, Qingdao, Shandong, China
Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 72
- Registration Number
- NCT04424381
- Locations
- 🇨🇳
Phase I Clinical Research Center, Qingdao, Shandong, China
Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 48
- Registration Number
- NCT04420871
- Locations
- 🇨🇳
Phase Ⅰ Clinical Research Center, Qingdao, Shandong, China
Bioequivalence of Cefprozil Granule in Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 60
- Registration Number
- NCT04414254
- Locations
- 🇨🇳
Phase I Clinical Research Center, Qingdao, Shandong, China
Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 48
- Registration Number
- NCT04411875
- Locations
- 🇨🇳
Phase Ⅰ Clinical Research Center, Qingdao, Shandong, China
PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 30
- Registration Number
- NCT04284202
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, China
Real World Study of Four PD-1 Agents in China
- Conditions
- Interventions
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 500
- Registration Number
- NCT03966456
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 46
- Registration Number
- NCT03735264
Study for Patients With Lung Metastatic Advanced Gastric Cancer and NSCLC Treated With Apatinib
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 187
- Registration Number
- NCT03629691
© Copyright 2024. All Rights Reserved by MedPath